Brain activity predicts response to medication in ADHD

July 1, 2018 by neuroCare Group
helping-children-learn-1.png

Today results from the large multicenter iSPOT-A study were published in European Neuropsychopharmacology, demonstrating that brain activity can assist in predicting response to medications in ADHD. In addition, this study clearly demonstrated gender differences in brain activity, where brain activity only predicted Psychostimulant response in males and not in females with ADHD. No differences in brain activity were found between children with and without ADHD, further demonstrating the value of brain imaging in prognosis rather than diagnosis.

An international group of researchers including researchers from Research Institute Brainclinics, Brainresource, University of Sydney, Utrecht University, Stanford School of Medicine, Westmead Hospital and Radboud University Nijmegen published results from the international multicenter iSPOT-A study (international Study to Predict Optimized Treatment in ADHD). This study recruited 336 children and adolescents with ADHD who were subsequently treated with methylphenidate and 158  children and adolescents without ADHD, and is the largest brain imaging study in ADHD focused on predicting response to Psychostimulant medications.

Researchers measured brain electrical activity, also called EEG or QEEG before treatment and clinical measures before and after treatment. When looking at differences in brain activity between participants with and without ADHD, no differences in brain activity were found. However, a clear difference was found between adolescents that did and did not respond to treatment with methylphenidate, albeit only for males, suggesting sex-specific differences in the etiology of ADHD.

Predicting Medication response in ADHD
The main aim of the study was to investigate if brain-based ‘biomarkers’, such as measured with QEEG, could predict treatment response. This study demonstrated that a single biomarker – namely Alpha Peak Frequency (APF) – was able to predict treatment response to methylphenidate for male adolescents. This study replicates and extends an earlier pilot-study that already suggested that this biomarker could predict treatment non-response (Arns et al., 2008).

“… the most striking aspect of the outcome of the study is that no difference in brain activity a measured using EEG was found between patients with and without ADHD, whereas brain activity was clearly different between male adolescents with ADHD that did and did not respond to methylphenidate, further demonstrating that brain imaging is better used for ‘prognosis’ and not for ‘diagnosis’. This finding offers hope and can prospectively be used to develop new treatments that are specifically aimed at this biomarker…’ said Martijn Arns, first author on the study.

This biomarker – possibly used in conjunction with other biomarkers identified in the iSPOT studies – could help assist in a future of Personalized Medicine or Precision Medicine, where biomarkers are used to objectively guide patients to the optimal treatment and can aid in the discovery of new treatments aimed at this subgroup.

To find out more about the iSPOT-A study, visit the Brainclinics.com website

Reference
Arns, M., Vollebregt, M.A., Palmer, D., Spooner, C., Gordon, E., Kohn, M., Clarke, S., Elliott, G., Buitelaar J.K. (2018).
Electroencephalographic biomarkers of methylphenidate response in Attention-Deficit/Hyperactivity Disorder.
European Neuropsychopharmacology. doi: 10.1016/j.euroneuro.2018.06.002

Arns, M., Gunkelman, J., Breteler, M., & Spronk, D. (2008). EEG phenotypes predict treatment outcome to
stimulants in children with ADHD. Journal of Integrative Neuroscience, 7(3), 421-38.

Click here to find out more about the Brainresource QEEG assessments, offered at neuroCare Clinics Australia.

Dr Arns is visiting neuroCare Clinics Australia in October 2018 to teach the 4-day Neurofeedback in ADHD and Insomnia workshop, visit our training page for further details.

neuroCare Group

neuroCare is a global brand in neuromodulation, active in research training in medication-free applications of TMS and Neurofeedback for mental wellness. neuroCare operates therapy centers all over the world, with clinics now open across Sydney and Melbourne.

Logo_neuroCare_bunt_Poster_vector_white

Personalising Mental Healthcare since 2001, using state-of-the-art neuromodulation to help children, adults and their families achieve lasting mental wellness.

www.neurocareclinics.com.au

Copyright neuroCare Group Pty Ltd. 2019. All rights reserved.